Systematic review and meta-analysis of the benefit of celecoxib in treating advanced non-small-cell lung cancer
Lilan Yi,* Wei Zhang,* Hongman Zhang, Jie Shen, Jingwen Zou, Peng Luo, Jian Zhang Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, People’s Republic of China *These authors contributed equally to this work Background: The clinical benefit of a s...
Saved in:
Main Authors: | Yi L (Author), Zhang W (Author), Zhang H (Author), Shen J (Author), Zou J (Author), Luo P (Author), Zhang J (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2018-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Metformin Synergistically Enhanced the Antitumor Activity of Celecoxib in Human Non-Small Cell Lung Cancer Cells
by: Nini Cao, et al.
Published: (2020) -
A Bibliometric Analysis of Triptolide and the Recent Advances in Treating Non-Small Cell Lung Cancer
by: Quancheng Yang, et al.
Published: (2022) -
Xiao-ai-ping injection adjunct with platinum-based chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis
by: Fanchao Feng, et al.
Published: (2020) -
Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis
by: Yu Lu, et al.
Published: (2023) -
Redox Status in Patients with non-small Cell Lung Cancer in Advanced Stages Treated with Polychemotherapy
by: Gretel Riverón Forment, et al.
Published: (2022)